Targacept (TRGT) Slammed Following RENAISSANCE Phase 3 Endpoint Miss
Tweet
Share
E-mailGet Alerts TRGT Hot Sheet
Join SI Premium – FREE
Targacept, Inc. (Nasdaq: TRGT), is getting slammed Tuesday morning, following reports that the first of four RENAISSANCE Phase 3 studies investigating the efficacy and tolerability of TC-5214 missed its primary endpoint. The studies were done in collaboration with AstraZeneca (NYSE: AZN).
Targacept is down over 56 percent ahead of the bell.
Targacept is down over 56 percent ahead of the bell.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 'No Discussions' Over Astrazeneca-Bristol Myers Deal, Senior Source Says - Reuters
- Exclusive-'No discussions' over AstraZeneca-Bristol Myers deal, senior source says
- SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies
Create E-mail Alert Related Categories
FDA, Insiders' Blog, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
